



November 10, 2016

Sage Therapeutics to Present at Society for Neuroscience 2016 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the Society for Neuroscience (SFN) 2016 Annual Meeting, taking place November 12-16, 2016 in San Diego, CA.

Below is the schedule for the presentations:

Date: Saturday, November 12, 2016

Poster Presentation Time: 1:00 p.m. - 5:00 p.m. PT

Location: Halls B-H, San Diego Convention Center

Poster Number: 34.04 / E6

Title: Pharmacology of the human ϵ subunit from the GABA_A receptors

Date: Monday, November 14, 2016

Poster Presentation Time: 1:00 p.m. - 4:00 p.m. PT

Location: Halls B-H, San Diego Convention Center

Poster Number: 407.11 / K17

Title: Neuroactive steroids exhibit synergistic interactions with barbiturates at the GABA_A receptor *in vitro* and this impacts on activity in an animal model of seizure

Date: Tuesday, November 15, 2016

Poster Presentation Time: 8:00 a.m. - 12:00 p.m. PT

Location: Halls B-H, San Diego Convention Center

Poster Number: 497.10 / F21

Title: Positive allosteric modulation of NMDA receptors ameliorate behavioral and electrophysiological phenotypes in a pre-clinical model of Smith-Lemli-Opitz Syndrome

Date: Wednesday, November 16, 2016

Poster Presentation Time: 8:00 a.m. - 12:00 p.m. PT

Location: Halls B-H, San Diego Convention Center

Poster Number: 690.11 / L8

Title: Phenytoin halts convulsions, but not electrographic seizure activity, in a rat model of status epilepticus, whereas both are eliminated by next generation neuroactive steroids

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20161110006437/en/): <http://www.businesswire.com/news/home/20161110006437/en/>

Investor Contact:

Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com

or

Media Contact:

Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com

Source: Sage Therapeutics

News Provided by Acquire Media